Efficacy and safety of paliperidone palmitate 6-month versus paliperidone palmitate 3-month long-acting injectable in patients with schizophrenia in Europe

Autor:	J. Antunes, C.G. Giron, J.H. Han, R. Alberio, A. Singh, M.P. García-Portilla, M. Pompili, U. Richarz, S. Gopal
Rok vydání:	2022
Zdroj:	Neuroscience Applied. 1:100282
ISSN:	2772-4085
DOI:	10.1016/j.nsa.2022.100282
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::b35fc58ea722f76b1b460042ec1aaab1 https://doi.org/10.1016/j.nsa.2022.100282 Zobrazit plný text záznamu